

Subscriber access provided by UNIV OF LOUISIANA

Preparation of Quinazolinoquinazolinones via a Cascade Approach

Mani Ramanathan, and Shiuh-Tzung Liu

J. Org. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.joc.8b02239 • Publication Date (Web): 25 Oct 2018 Downloaded from http://pubs.acs.org on October 26, 2018

Just Accepted

Note

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

Preparation of Quinazolinoquinazolinones via a Cascade Approach Mani Ramanathan and Shiuh-Tzung Liu* Department of Chemistry, National Taiwan University, Taipei 106, Taiwan Corresponding author. E-mail: stliu@ntu.edu.tw TITLE RUNNING HEAD: Preparation of quinazolinoquinazolinones Graphic Abstract (TOC) R-CN, 80 °C CO₂Me

ABSTRACT. A one-pot synthesis of quinazolino[3,4-*a*]quinazolin-13-ones has been realized from the direct reaction of *o*-(methoxycarbonyl)benzenediazonium salts, nitriles and 2-cyanoanilines in moderate to good yields. This method utilizes the *in situ* generation of reactive *N*-arylnitrilium ion, which undergoes further amination/tandem cyclization/amidation to deliver the desired polycyclic scaffolds with consecutive formation of four N-C bonds. Flexibility in substitution patterns, mild reaction conditions and operational simplicity are the salient features of this methodology.

KEYWORDS. Quinazolinoquinazolinone, Diazonium, Cascade reaction, nitrilium.

The polynuclear *N*-heterocyclic compounds with fused multi-ring skeletons are not only of considerable interest to the drug and dye industry but also of great importance in the realm of biological sciences.¹ Especially, the combination of rigid scaffolds with unique installation of functional groups, has evoked special interest in synthetic organic chemistry. Among the various *N*-heterocycles, quinazolin-4(3*H*)-one fused polycyclic frameworks are privileged owing to their prevalence in several natural products such as, Luotonin A,² Rutaecarpine,³ Tryptanthrin,⁴ Cephalanthrin A,⁵ Phaitanthrin (A and B)⁶ and Cruciferane⁷ (Scheme 1). On the other hand, quinazolino[3,4-*a*]quinazolin-13-one is particularly fascinating motif due to its ubiquitous structural features.⁸ Yet, despite the inspiring skeletal diversity, synthetic efforts towards quinazolino-quinazolinone remain largely underdeveloped.





In 1984, Yamada *et al.* described the synthesis of 13*H*-quinazolino[3,4-*a*]quinazolin-13-ones from benzoxazine-4-ones and 2-cyanoanilines at elevated temperature (Scheme 2a).^{8a} In this preparation, 4-iminoquinazoline is believed to be the key intermediate. Venkateswarlu's group demonstrated a four step synthesis from 2-aminobenzamide and 2-nitrobenzoic acid (Scheme

2b), in which the key intermediate dihydro-13*H*-quinazolino(3,4-*a*)quinazolin-13-one was converted into quinazolino-quinazolinones upon the oxidative aromatization.^{8b} In addition, synthesis of 6-unsubstituted analogue was reported by Proença and co-workers involving the acid mediated two step reaction of 2-cyanoanilines with triethylorthoformate (Scheme 2c), where the title compound was obtained by the hydrolysis of the corresponding imine-acid salts.^{8c} Finally, Nanni's group observed a minor formation of 6-unsubstituted 13*H*-quinazolino[3,4-*a*]quinazolin-13-one in the multi-step reaction of 2-[4-imino-2-thioxa-1,4-dihydro-3(2*H*)-quinazolinyl]benzonitrile with Mn(OAc)₃.^{8d} These existing synthetic routes require multi-step procedures, complicated pre-functionalized sites and harsh conditions. Thus, development of a strategically unique approach that can directly deliver fused quinazolino-quinazolinones from readily available substrates in one-step remains elusive.

Scheme 2. Various Approaches Towards Quinazolino-quinazolinones.



Aryldiazonium salts are undoubtedly one of the most important precursors due to their widespread applications in organic synthesis.⁹ Ease of preparation from a wide range of commercially available anilines, excellent leaving group ability of N_2 and inherent electrophilicity render these compounds an attractive alternative to aromatic halides. Notably,

synthetic applications involving *in situ* generation of nitrilium intermediate from aryldiazonium salts and nitriles has gained extensive attention owing to their versatile reactivity and synthetic flexibility.¹⁰ Based on our recent developments on aryldiazonium salts based tandem annulations,¹¹ we envisaged whether an *in situ* generation of suitably functionalized NaryInitrilium intermediate could be utilized to achieve a mild approach of quinazolinoquinazolin-13-ones, via an intermolecular cascade/tandem cyclization process. Indeed, as a proof-of-concept, recently we developed a synthesis of functionalized quinazolin-4(3H)-imines via an annulation protocol.^{11b} This strategy led us to envision that further advancements might be plausible by utilizing aryldiazonium precursors. Herein, we disclose a convenient and mild method for the preparation of substituted quinazolino-quinazolinone derivatives from o-ester substituted aryldiazonium salts, nitriles and 2-cyanoanilines via in situ generation of NaryInitrilium intermediate I from the reaction of 2-(methoxycarbonyl)aryldiazonium salt and nitrile followed by a tandem amination/cascade cvclization/amidation to afford the fused quinazolino-quinazolinones (Scheme 3). Substitution reaction of aryldiazonium salts with nitrile components is a known strategy to afford N-aryInitrilium intermediates with the loss of N₂ and this intermediate can further undergo reaction with various amino and carbon nucleophiles.¹⁰⁻¹¹

Scheme 3. Our Proposed Synthetic Approach



ACS Paragon Plus Environment

To explore the feasibility, we examined the reaction of **1a** with 2-cyanoaniline (**2a**) in the presence of anhydrous MeCN under various conditions (Table 1). It was observed that, at room temperature, desired product was found only in trace amounts. Guided by our previous learnings,^{11a-11d} when the reaction was conducted at 80 °C for 2h, **3a** was isolated in 71% yield (Table 1, entry 2). To our delight, when the reaction was carried out at 80 °C for 5 h, 6-methyl-13*H*-quinazolino[3,4-*a*]quinazolin-13-one (**3a**) was isolated in 78% yield (Table 1, entry 3). Lowering the reaction temperature with extended time resulted in a diminished yield (Table 1, entry 4). Attempts to reduce the quantity of nitrile in the presence of other co-solvents such as, DMSO, DMF and DCE were unfruitful and led to inferior results (Table 1, entries 5-7).

Table 1. Reaction Optimization^a

$\begin{array}{c} & CO_2Me \\ & + \\ & N_2^+BF_4^- \end{array} \\ & H_2 \end{array}$		MeCN		
1a	2a			3a
entry	solvent	T (°C)	<i>t</i> (h)	Yield ^b
1	MeCN	rt	24	trace
2	MeCN	80	2	71%
3	MeCN	80	5	78%
4	MeCN	50	12	56%
5°	MeCN/dmso	80	12	ND ^d
6°	MeCN/DMF	100	12	ND ^d
7°	MeCN/DCE	reflux	12	ND ^d

^a Reaction conditions: a mixture of **1a** (0.40 mmol), **2a** (0.48 mmol) and acetonitrile (2 mL) in a sealed tube. ^b yields given refer to isolated yields. ^c MeCN (1 mL) in solvent (2 mL). ^d ND = not detected.

With these optimal conditions in hand, we then systematically studied the scope of this reaction with varieties of substituted 2-cyanoanilines in combination with benzenediazonium salt (1a) and acetonitrile (Table 2). Regardless of the position, various halogenated 2-cvanoanilines were participated in the reaction and provided the corresponding products in good isolated yields (Table 2, **3a-3d**). Remarkably, anthralonitirle bearing ortho-chloro substituent readily reacted (Table 2, 3g). All these halogenated quinazolino-quinazolinones could serve as potential building blocks for further synthetic conversions. Substrates with phenyl and 1-naphthyl substituents smoothly participated in the transformation and afforded the respective arylated product in good yields (Table 2, **3e-3f**). In particular, 2-amino-5-(naphthalen-1-yl)benzonitrile with acetonitrile, providing 6-methyl-10- $(\alpha$ -naphthyl)quinazolino[3,4-a in reacted a]quinazolinones **3f** in 73% yield. It is noted that, antharalonitrile with diketo functionality did not led to the desired product (Eq. 1). Heteroaromatic counterparts such as, 2aminonicotinonitrile, 2-aminothiophene-3-carbonitrile and linear 3-aminocrotononitrile were failed to give the corresponding products despite our extensive efforts.



Table 2. Reaction of 1a with various 2-cyanoanilines in MeCN^a



$$Ph \underbrace{\bigcirc}_{O} CN + 1a \xrightarrow{CH_3CN} complex mixture$$
(1)

Next, we studied the scope and limitation of this method with various nitrile components (Table 3). A series of aliphatic nitriles such as, 1°, 2°, 3° and cyclic nitriles were involved in the reaction efficiently, leading to the formation of **4a-4d** in moderate to excellent yields. Similarly, profound flexibility can be exerted concerning aryl nitriles; thus, variously substituted benzonitriles were utilized in this reaction to furnish 6-arylsubstituted quinazolino-quinazolinones in yields ranging from 54%-63% (Table 3, **4e-4g**). The sensitive cyano functionality on the alkyl linkage remains intact, thus offering ample potential for further

synthetic elaboration. To our delight, benzylnitrile was also amenable in this reaction to deliver the corresponding 6-benzylated product in good yields (Table 3, **4i**). Again, reaction of **1a** with 2-amino-5-(naphthalen-1-yl)benzonitrile in various nitriles yielded the corresponding products in good yields (Table 3, **4j**-**4k**). Intriguingly, when 2-amino-5-(naphthalen-1-yl)benzonitrile was treated with benzylnitrile, a mixture of isomers **4l** and **4l**' were formed as an inseparable mixture, presumably due to the similar stability of conjugation. Unfortunately, thiophene-2-carbonitrile and α -chloroacetonitirle were failed to give the corresponding products.







^aReaction conditions: **1a** (0.40 mmol) and **2** (1.2 eq) in nitrile (2 mL) were heated to 80 °C for 5 h; isolated yields are reported in brackets.

Finally, we contemplated the scope of this tandem process with variously substituted *o*-(methoxycarbonyl)benzenediazonium salts **1b-1e** (Table 4). The efficiency was slightly affected by variations of substituents on the aryl ring. A series of aryldiazonium salts bearing substituents at *para* and *meta* positions underwent the reaction smoothly to provide the corresponding 13*H*-quinazolino(3,4-*a*)quinazolin-13-ones in acceptable yields (Table 4, **5a-5c**) with the exception of 3,4-dimethoxy substituted precursor **1f** (Eq. 2). To further challenge, we also tested the reaction in presence of a functionality of benzyl ester and found that the reaction proceeded smoothly to give **5d** in 44% yield (Table 4, **5d**).

Table 4. Reaction Scope of Aryldiazonium Salts^a





^a Reaction conditions: aryldiazonium salt 1 (1.0 eq) and 2 (1.2 eq) in acetonitrile (2 mL) were heated to 80 °C for 5 h; isolated yields are given in brackets.



Intriguingly, when 2-(methoxycarbonyl)-6-methylbenzenediazonium salt (**1g**) bearing an adjacent methyl group was employed in this reaction, we observed the formation of quinazolin-4-(3H)-imine (**6**) and *N*-arylquinazolin-3-(4H)-one (**7**), instead of the corresponding product, 4,6-dimethyl-13H-quinazolino[3,4-a]quinazolin-13-one probably owing to the steric reason (Eq. 3).



For a practical utility of this method, a gram scale synthesis of **3a** was performed. Typically, treatment of **1a** (1 g) with anthralonitrile **2a** (0.52 g) in acetonitrile (20 mL) furnished **3a** (0.87 g, 84%) and 2-(2-methyl-4-oxo-quinazolin-3(4*H*)-yl)benzonitrile (**8**) in 4% yield (Eq. 4). (Caution: *Aryldiazonium salts are dangerously explosive upon heating, and reactions must be carried out using necessary precautions*).



In summary, we have developed a unique transition-metal free strategy for accessing diverse polycyclic quinazolino-quinazolinones scaffolds from a simple set of readily available precursors through an intermolecular amination/tandem cyclization/amidation of *in situ* generated *N*-arylnitrilium intermediate from the reaction of diazonium salt with a nitrile functionality. The salient features of this report include mild reaction condition, broad substrate scope, experimental simplicity and consecutive formation of four C-N bonds, making this approach with potential for further synthetic applications.

Experimental Section

General information. ¹H and ¹³C NMR were recorded in a 400 MH_z spectrometer in CDCl₃ and CD₃CN referenced to TMS. All the nitriles were dried over activated 4A^o molecular sieves and solid nitriles were purchased and used without any further drying. All the anilines were commercially purchased and used for diazotization without further purification. Other chemicals were used as purchased. Flash chromatography was performed using silica gel 230-400 mesh. Aryldiazonium salts were prepared according to the literature procedure. In cases of known compounds, their spectral data were compared with the literature values. Melting points were determined on a Fargo MP-1D instrument. Unless otherwise noted, all the reactions were performed without any special precautions. Compounds **2b**,^{12a} **2c**,^{12b} **2d**,^{12c}, 2g,^{12d} and **2h**^{12e} were prepared according to the literature methods, whereas the preparation of **2e** and **2f** were achieved by a Suzuki coupling.^{12b}

General procedure for preparing aryldiazonium tetrafluoroborate.

Methyl-2-aminobenzoate (1g, 6.61 mmol, 1.0 equiv.) was dissolved in a mixture of water (4 mL) and 50% aqueous hydrofluroboric acid (2.4 mL, 13.23 mmol, 2.0 equiv.). The mixture was cooled to 0 $^{\circ}$ C and a solution of NaNO₂ (0.46 g, 6.68 mmol in 4 mL of water) was added slowly. The resulting reaction mixture was stirred at 0 $^{\circ}$ C for 30 minutes and the precipitate was collected by filtration. The solid product was dissolved in minimum acetone and reprecipitated using diethyl ether to yield 2-(methoxycarbonyl)benzenediazonium tetrafluoroborate which was dried under vacuum. (white solid, 1.45 g, 88%). The spectral data are in agreement with the literature reported.¹³

2-(Methoxycarbonyl)-4-methylbenzenediazonium tetrafluoroborate (1b).

901 mg, 94%, pale pink solid: ¹H NMR (400 MHz, DMSO-d₆) δ 8.81 (d, *J* = 8.4 Hz, 1H), 8.27 (s, 1H), 8.06 (d, *J* = 8.4 Hz, 1H), 4.02 (s, 3H), 2.64 (s, 3H); ¹³C{¹H} NMR (100 MHz, DMSO-d₆) δ 161.5, 154.3, 135.5, 135.2, 133.0, 130.4, 111.8, 54.0, 22.1; HRMS (ESI-TOF) calcd. For C₉H₉N₂O₂ (M-BF₄)⁺ m/z = 177.0659, found 177.0667.

5-Bromo-2-(methoxycarbonyl)benzenediazonium tetrafluoroborate (1c).

630 mg, 74%, brown solid: ¹H NMR (400 MHz, DMSO-d₆) δ 9.27 (s, 1H), 8.61 (d, *J* = 8.4 Hz, 1H), 8.29 (d, *J* = 8.4 Hz, 1H), 4.02 (s, 3H); ¹³C{¹H} NMR (100 MHz, DMSO-d₆) δ 160.9, 143.7, 136.8, 133.3, 129.5, 126.9, 117.3, 54.3; HRMS (ESI-TOF) calcd. For C₈H₆⁷⁹BrN₂O₂ (M-BF₄)⁺ m/z = 240.9607, found 240.9612; HRMS (ESI-TOF) calcd. For C₈H₆⁸¹BrN₂O₂ (M-BF₄)⁺ m/z = 242.9587, found 242.9595.

4-Iodo-2-(methoxycarbonyl)benzenediazonium tetrafluoroborate (1d).

569 mg, 84%, white solid: ¹H NMR (400 MHz, DMSO-d₆) δ 8.70 (d, J = 8.4 Hz, 2H), 8.58 (d, J = 8.0 Hz, 1H), 4.00 (s, 3H); ¹³C{¹H} NMR (100 MHz, DMSO-d₆) δ 160.4, 143.9, 140.7, 135.0, 130.4, 114.6, 113.6, 54.2; HRMS (ESI-TOF) calcd. For C₈H₆IN₂O₂ (M-BF₄)⁺ m/z = 288.9468, found 288.9474.

4-((Benzyloxy)carbonyl)-2-(methoxycarbonyl)benzenediazonium tetrafluoroborate (1e).

770 mg, 72%, off-white solid: ¹H NMR (400 MHz, DMSO-d₆) δ 9.53 (s, 1H), 8.81 (d, *J* = 7.6 Hz, 1H), 8.50 (d, *J* = 8.0 Hz, 1H), 7.53 (d, *J* = 6.8 Hz, 2H), 7.43 (d, *J* = 7.6 Hz, 3H), 5.46 (s, 2H), 4.05 (s, 3H); ¹³C{¹H} NMR (100 MHz, DMSO-d₆) δ 161.8, 160.8, 140.8, 135.5, 135.0, 134.8, 133.5, 132.8, 128.6 (2C), 128.5, 117.0, 68.0, 54.4; HRMS (ESI-TOF) calcd. For C₁₆H₁₃N₂O₄ (M-BF₄)⁺ m/z = 297.0870, found 297.0880.

4,5-Dimethoxy-2-(methoxycarbonyl)benzenediazonium tetrafluoroborate (1f).

677 mg, 77%, brown solid: ¹H NMR (400 MHz, DMSO-d₆) δ 8.52 (s, 1H), 7.79 (s, 1H), 4.13 (s, 3H), 4.00 (s, 3H), 3.96 (s, 3H); ¹³C{¹H} NMR (100 MHz, DMSO-d₆) δ 161.2, 158.2, 151.6, 127.5, 115.7, 114.4, 104.0, 57.9, 57.3, 53.9; HRMS (ESI-TOF) calcd. For C₁₀H₁₁N₂O₄ (M-BF₄)⁺ m/z = 223.0713, found 223.0724.

2-(Methoxycarbonyl)-6-methylbenzenediazonium tetrafluoroborate (1g).

870 mg, 91%, white solid: ¹H NMR (400 MHz, DMSO-d₆) δ 8.27 (d, *J* = 4.8 Hz, 2H), 8.13 (t, *J* = 4.8 Hz, 1H), 4.03 (s, 3H), 2.83 (s, 3H); ¹³C{¹H} NMR (100 MHz, DMSO-d₆) δ 161.6, 146.9, 140.2, 136.7, 130.4, 130.3, 115.0, 54.1, 18.4; HRMS (ESI-TOF) calcd. For C₉H₉N₂O₂ (M-BF₄)⁺ m/z = 177.0659, found 177.0663.

General Procedure for the synthesis of 13*H*-quinazolino[3,4-*a*]quinazolin-13-ones.

In a dry 10 mL glass sealed tube, aryldiazonium salt (0.40 mmol) and 2-cyanoaniline (0.48 mmol) were suspended in 2 mL of anhydrous nitrile. The tube was sealed with a Teflon screw cap and heated in an oil bath (80 °C) for 5h. After cooling to room temperature, the reaction mixture was diluted with ethyl acetate (30 mL) and washed with saturated aq. NaHCO₃ solution (10 mL). Organic Layer was dried over anhydrous Na₂SO₄. Solvents removed and purified by column chromatography (Eluent 40% to 70% EtOAc:Hexane) to obtain the desired compounds.

6-Methyl-13*H*-quinazolino[3,4-*a*]quinazolin-13-one (3a).^{8b}

 81 mg, 78%, pale yellow solid: mp 227-229 °C: ¹H NMR (400 MHz, CDCl₃) δ 8.26 (dd, J = 8.0, 1.2 Hz, 1H), 8.32 (d, J = 7.6 Hz, 1H), 7.76 (ddd, J = 15.4, 7.6, 1.6 Hz, 1H), 7.72 (d, J = 3.2 Hz, 2H), 7.64 (d, J = 8.0 Hz, 1H), 7.61-7.57 (m, 1H), 7.51 (ddd, J = 15.2, 7.6, 0.8 Hz, 1H), 2.95 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 167.2, 153.2, 148.2, 143.3, 136.7, 134.8, 131.9, 128.2, 128.1, 128.0, 126.7, 126.1, 122.9, 120.4, 119.7, 26.0; HRMS (ESI-TOF) calcd. For C₁₆H₁₂N₃O (M+H)⁺ m/z = 262.0980, found 262.0984.

10-Chloro-6-methyl-13*H*-quinazolino[3,4-*a*]quinazolin-13-one (3b).

94 mg, 81%, off-white solid: mp 228-229 °C: ¹H NMR (400 MHz, CDCl₃) δ 8.58 (d, *J* = 2.4 Hz, 1H), 8.31 (d, *J* = 8.0 Hz, 1H), 7.73 (d, *J* = 3.6 Hz, 2H), 7.68 (dd, *J* = 8.8, 2.4 Hz, 1H), 7.62-7.57 (m, 2H), 2.95 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 166.9, 152.1, 148.5, 141.7, 136.5, 135.1, 133.9, 132.0, 128.4, 128.3, 127.8, 125.9, 122.9, 120.8, 120.4, 26.1; HRMS (ESI-TOF) calcd. For C₁₆H₁₁³⁵ClN₃O (M+H)⁺ m/z = 296.0591, found 296.0599; HRMS (ESI-TOF) calcd. For C₁₆H₁₁³⁷ClN₃O (M+H)⁺ m/z = 298.0561, found 298.0624.

10-Bromo-6-methyl-13*H*-quinazolino[3,4-*a*]quinazolin-13-one (3c).

92 mg, 68%, white solid: mp 273-274 °C: ¹H NMR (400 MHz, CDCl₃) δ 8.83 (d, J = 2.0 Hz, 1H), 8.38 (d, J = 7.6 Hz, 1H), 7.86 (dd, J = 8.8, 2.4 Hz, 1H), 7.77-7.72 (m, 2H), 7.64 (ddd, J = 13.8, 6.6, 2.0 Hz, 1H), 7.54 (d, J = 8.4 Hz, 1H), 2.96 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 166.9, 152.0, 148.8, 141.9, 138.0, 136.5, 132.1, 129.2, 128.5 (2C), 127.8, 123.1, 121.9, 121.1, 120.4, 26.0; HRMS (ESI-TOF) calcd. For C₁₆H₁₁⁷⁹BrN₃O (M+H)⁺ m/z = 340.0085, found 340.0086; HRMS (ESI-TOF) calcd. For C₁₆H₁₁⁸¹BrN₃O (M+H)⁺ m/z = 342.0065, found 342.0073.

10-Iodo-6-methyl-13*H*-quinazolino[3,4-*a*]quinazolin-13-one (3d).

101 mg, 66%, white solid: mp 234-235 °C: ¹H NMR (400 MHz, CDCl₃) δ 9.05 (d, *J* = 2.0 Hz, 1H), 8.38 (d, *J* = 8.0 Hz, 1H), 8.06 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.77-7.71 (m, 2H), 7.67-7.63 (m, 1H), 7.43-7.42 (m, 1H), 2.96 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 167.0, 151.8, 148.8,

143.6, 142.6, 136.6, 135.4, 132.1, 128.5 (2C), 127.8, 123.1, 121.2, 120.4, 92.8, 26.1; HRMS (ESI-TOF) calcd. For $C_{16}H_{11}IN_{3}O$ (M+H)⁺ m/z = 387.9947, found 387.9961.

6-Methyl-10-(o-tolyl)-13H-quinazolino[3,4-a]quinazolin-13-one (3e).

106 mg, 76%, off-white solid: mp 119-120 °C: ¹H NMR (400 MHz, CDCl₃) δ 8.65 (d, *J* = 2.0 Hz, 1H), 8.36 (d, *J* = 8.0 Hz, 1H), 7.77 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.74-7.70 (m, 3H), 7.65-7.59 (m, 1H), 7.27-7.23 (m, 4H), 2.99 (s, 3H), 2.26 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 167.2, 153.3, 148.0, 142.2, 140.0, 136.7, 136.1 (2C), 135.1, 131.9, 130.4, 129.8, 128.3, 128.1, 127.9, 126.8, 125.9 (2C), 123.0, 120.3, 119.6, 26.0, 20.4; HRMS (ESI-TOF) calcd. For C₂₃H₁₈N₃O (M+H)⁺ m/z = 352.1450, found 352.1457.

6-Methyl-10-(naphthalen-1-yl)-13*H*-quinazolino[3,4-*a*]quinazolin-13-one (3f).

113 mg, 73%, off-white solid: mp 283-284 °C: ¹H NMR (400 MHz, CDCl₃) δ 8.83 (d, *J* = 2.0 Hz, 1H), 8.37 (d, *J* = 8.0 Hz, 1H), 7.95 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.89 (t, *J* = 8.4 Hz, 2H), 7.81-7.71 (m, 4H), 7.62 (ddd, *J* = 13.4, 6.4, 2.4 Hz, 1H), 7.54-7.50 (m, 1H), 7.49-7.46 (m, 2H), 7.41 (t, *J* = 8.0 Hz, 1H), 3.01 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 167.2, 153.3, 148.2, 142.5, 141.0, 138.2, 136.9, 136.7, 133.7, 131.9, 131.2, 128.4 (2C), 128.3, 128.2, 127.6, 127.5, 126.4, 126.0, 125.9, 125.3 (2C), 123.0, 120.3, 119.9, 26.1; HRMS (ESI-TOF) calcd. For C₂₆H₁₈N₃O (M+H)⁺ m/z = 388.1450, found 388.1454.

8-Chloro-6-methyl-13*H*-quinazolino[3,4-*a*]quinazolin-13-one (3g).

97 mg, 83%, off-white solid: mp 233-234 °C: ¹H NMR (400 MHz, CDCl₃) δ 8.53 (dd, J = 8.0, 1.2 Hz, 1H), 8.33 (d, J = 7.6 Hz, 1H), 7.82 (dd, J = 8.0, 1.2 Hz, 1H), 7.75-7.72 (m, 2H), 7.64-7.60 (m, 1H), 7.42 (t, J = 8.0 Hz, 1H), 3.01 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 167.0, 152.6, 149.3, 140.1, 136.5, 134.9, 132.1, 130.9, 128.4, 128.3, 128.0, 125.4, 122.9, 121.5, 120.4, 26.2; HRMS (ESI-TOF) calcd. For C₁₆H₁₁³⁵ClN₃O (M+H)⁺ m/z = 296.0591, found 296.0599; HRMS (ESI-TOF) calcd. For C₁₆H₁₁³⁷ClN₃O (M+H)⁺ m/z = 298.0561, found 298.0602.

6-Propyl-13*H*-quinazolino[3,4-*a*]quinazolin-13-one (4a).

87 mg, 76%, pale yellow solid: mp 238-239 °C: ¹H NMR (400 MHz, CDCl₃) δ 8.68 (dd, J = 8.0, 1.2 Hz, 1H), 8.36 (dd, J = 7.6, 1.6 Hz, 1H), 7.82-7.78 (m, 1H), 7.74-7.66 (m, 3H), 7.62 (ddd, J = 14.8, 7.4, 1.2 Hz, 1H), 7.55 (ddd, J = 15.2, 7.4, 1.2 Hz, 1H), 3.19 (t, J = 7.6 Hz, 2H), 1.91 (sex, J = 7.6 Hz, 2H), 0.91 (t, J = 7.2 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 167.5, 153.3, 151.9, 143.5, 136.7, 134.8, 131.8, 128.3, 128.1, 128.0, 126.7, 126.5, 123.1, 120.4, 119.7, 39.0, 22.3, 13.6; HRMS (ESI-TOF) calcd. For C₁₈H₁₆N₃O (M+H)⁺ m/z = 290.1293, found 290.1291.

6-Isopropyl-13*H*-quinazolino[3,4-*a*]quinazolin-13-one (4b).

54 mg, 47%, brown solid: mp 178-179 °C: ¹H NMR (400 MHz, CDCl₃) δ 8.63 (dd, *J* = 8.0, 1.2 Hz, 1H), 8.32 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.77 (ddd, *J* = 11.6, 7.4, 1.2 Hz, 1H), 7.75-7.67 (m, 2H), 7.60-7.55 (m, 2H), 7.51 (ddd, *J* = 14.4, 7.0, 1.2 Hz, 1H), 3.74 (hept, *J* = 6.4 Hz, 1H), 1.39 (d, *J* = 6.8 Hz, 6H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 167.5, 157.2, 153.3, 143.7, 136.7, 134.7, 131.7, 128.1, 127.9, 127.8, 126.6, 126.5, 123.0, 120.2, 119.5, 33.5, 22.3; HRMS (ESI-TOF) calcd. For C₁₈H₁₆N₃O (M+H)⁺ m/z = 290.1293, found 290.1290.

6-(*tert*-Butyl)-13*H*-quinazolino[3,4-*a*]quinazolin-13-one (4c).

51 mg, 42%, brown sticky solid: ¹H NMR (400 MHz, CDCl₃) δ 8.57 (dd, *J* = 8.4, 1.2 Hz, 1H), 8.22 (dd, *J* = 7.2, 1.2 Hz, 1H), 7.77 (ddd, *J* = 15.2, 7.6, 1.6 Hz, 1H), 7.69 (d, *J* = 8.0 Hz, 1H), 7.63-7.52 (m, 3H), 7.50-7.48 (m, 1H), 1.42 (s, 9H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 167.7, 159.4, 154.3, 143.5, 138.5, 134.7, 130.7, 127.9, 127.7, 127.3, 126.5, 126.2, 122.3, 122.0, 119.2, 42.6, 32.0; HRMS (ESI-TOF) calcd. For C₁₉H₁₈N₃O (M+H)⁺ m/z = 304.1450, found 304.1441.

6-Cyclopropyl-13*H*-quinazolino[3,4-*a*]quinazolin-13-one (4d).

81 mg, 69%, brown solid: mp 195-196 °C: ¹H NMR (400 MHz, CDCl₃) δ 8.66 (dd, *J* = 8.0, 0.8 Hz, 1H), 8.37 (dd, *J* = 8.0, 1.6 Hz, 1H), 8.26 (d, *J* = 8.4 Hz, 1H), 7.77-7.68 (m, 2H), 7.62-7.57 (m, 2H), 7.48 (t, *J* = 8.0 Hz, 1H), 2.34 (hept, *J* = 4.8 Hz, 1H), 1.68-1.64 (m, 2H), 1.30-1.26 (m,

2H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 167.6, 153.2, 153.0, 143.8, 136.9, 134.7, 131.5, 128.2,

127.9, 127.3, 126.8, 126.2, 123.0, 120.7, 119.6, 17.4, 13.4; HRMS (ESI-TOF) calcd. For $C_{18}H_{14}N_{3}O (M+H)^+ m/z = 288.1137$, found 288.1136.

6-Phenyl-13*H*-quinazolino[3,4-*a*]quinazolin-13-one (4e).

80 mg, 63%, off-white solid: mp 143-144 °C: ¹H NMR (400 MHz, CDCl₃) δ 8.75 (d, *J* = 8.0 Hz, 1H), 8.29 (d, *J* = 7.6 Hz, 1H), 7.83 (d, *J* = 3.6 Hz, 2H), 7.61-7.57 (m, 3H), 7.50-7.44 (m, 1H), 7.43-7.39 (m, 3H), 7.26-7.22 (m, 1H), 7.96 (d, *J* = 8.4 Hz, 1H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 167.6, 153.6, 149.3, 143.7, 137.6, 135.5, 135.0, 131.1, 131.0, 129.1, 128.6, 128.5, 127.8, 127.5, 127.4, 126.8, 122.3, 121.9, 119.9; HRMS (ESI-TOF) calcd. For C₂₁H₁₄N₃O (M+H)⁺ m/z = 324.1137, found 324.1136.

6-(o-Tolyl)-13H-quinazolino[3,4-a]quinazolin-13-one (4f).

76 mg, 57%, off-white solid: mp 274-275 °C: ¹H NMR (400 MHz, CDCl₃) δ 8.80 (d, J = 8.0, 0.8 Hz, 1H), 8.32 (dd, J = 7.6, 1.6 Hz, 1H), 7.87-7.81 (m, 2H), 7.62 (ddd, J = 11.2, 4.8, 2.0 Hz, 1H), 7.50 (dd, J = 7.6, 0.8 Hz, 1H), 7.45-7.37 (m, 2H), 7.30 (t, J = 7.6 Hz, 1H), 7.23-7.19 (m, 2H), 6.95 (d, J = 8.8 Hz, 1H), 2.12 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 167.4, 153.2, 149.4, 143.5, 137.3, 135.7, 135.0 (2C), 131.6, 131.4, 130.7, 129.3, 128.7, 127.9, 127.7, 127.3, 127.0 (2C), 122.3, 120.3, 120.0, 19.6; HRMS (ESI-TOF) calcd. For C₂₂H₁₆N₃O (M+H)⁺ m/z = 338.1293, found 338.1292.

6-(p-Tolyl)-13H-quinazolino[3,4-a]quinazolin-13-one (4g).

73 mg, 54%, pale yellow solid: mp 226-227 °C: ¹H NMR (400 MHz, CDCl₃) δ 8.75-8.72 (m, 1H), 8.29-8.27 (m, 1H), 7.82-7.80 (m, 2H), 7.59-7.55 (m, 1H), 7.50-7.48 (m, 2H), 7.43 (ddd, *J* = 15.0, 7.4, 1.2 Hz, 1H), 7.28-7.24 (m, 1H), 7.21-7.19 (m, 2H), 7.01 (d, *J* = 8.4 Hz, 1H), 2.38 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 167.7, 153.7, 149.5, 143.8, 141.7, 137.7, 135.0, 132.7,

130.9, 129.8, 128.5, 128.4, 127.7, 127.5, 127.3, 126.8, 122.2, 121.9, 119.9, 21.5; HRMS (ESI-TOF) calcd. For $C_{22}H_{16}N_3O$ (M+H)⁺ m/z = 338.1293, found 338.1294.

5-(13-Oxo-13*H*-quinazolino[3,4-*a*]quinazolin-6-yl)pentanenitrile (4h).

104 mg, 79%, pale yellow sticky solid: ¹H NMR (400 MHz, CDCl₃) δ 8.64 (dd, *J* = 8.0, 0.8 Hz, 1H), 8.33 (dd, *J* = 8.0, 1.6 Hz, 1H), 7.81-7.77 (m, 1H), 7.72 (ddd, *J* = 15.6, 8.0, 1.6 Hz, 1H), 7.69 (dd, *J* = 8.0, 0.8 Hz, 1H), 7.65-7.59 (m, 2H), 7.54 (ddd, *J* = 15.2, 7.8, 1.2 Hz, 1H), 3.25 (t, *J* = 7.2 Hz, 2H), 2.12-2.04 (m, 2H), 1.73-1.66 (m, 2H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 167.3, 153.1, 150.6, 143.2, 136.4, 134.9, 132.0, 128.3, 128.2 (2C), 126.6, 126.5, 123.1, 120.3, 119.6, 119.1, 36.2, 27.5, 24.7, 17.0; HRMS (ESI-TOF) calcd. For C₂₀H₁₇N₄O (M+H)⁺ m/z = 329.1402, found 329.1397.

6-Benzyl-13*H*-quinazolino[3,4-*a*]quinazolin-13-one (4i).

101 mg, 74%, pale yellow solid: mp 208-209 °C: ¹H NMR (400 MHz, CDCl₃) δ 8.66 (d, *J* = 8.0 Hz, 1H), 8.32 (dd, *J* = 7.2, 1.2 Hz, 1H), 7.83-7.74 (m, 2H), 7.69 (d, *J* = 8.4 Hz, 1H), 7.65 (dd, *J* = 7.2, 1.6 Hz, 1H), 7.61-7.54 (m, 2H), 7.29-7.20 (m, 5H), 4.55 (s, 2H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 167.3, 153.4, 149.9, 143.4, 136.7, 135.4, 134.8, 131.9, 128.9, 128.5, 128.4, 128.3, 128.2, 127.4, 126.8, 126.7, 122.9, 120.6, 119.8, 42.7; HRMS (ESI-TOF) calcd. For C₂₂H₁₅N₃O (M+H)⁺ m/z = 338.1293, found 338.1297.

10-(Naphthalen-1-yl)-6-propyl-13*H*-quinazolino[3,4-*a*]quinazolin-13-one (4j).

109 mg, 66%, pale yellow solid: mp 212-213 °C: ¹H NMR (400 MHz, CDCl₃) δ 8.81 (d, *J* = 2.0 Hz, 1H), 8.33 (d, *J* = 7.2 Hz, 1H), 7.93 (dd, *J* = 8.4, 2.0 Hz, 1H), 7.88 (t, *J* = 8.4 Hz, 2H), 7.82-7.79 (m, 2H), 7.71-7.67 (m, 2H), 7.61-7.58 (m, 1H), 7.52 (d, *J* = 7.2 Hz, 1H), 7.49-7.45 (m, 2H), 7.42-7.38 (m, 1H), 3.22 (t, *J* = 7.6 Hz, 2H), 1.92 (sex, *J* = 7.2 Hz, 2H), 0.92 (t, *J* = 7.2 Hz, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 167.4, 153.2, 152.0, 142.6, 140.8, 138.2, 136.8, 136.7, 133.7, 131.8, 131.1, 128.3 (2C), 128.2, 128.0, 127.5, 127.4, 126.4, 126.3, 125.9, 125.3, 125.2,

123.0, 120.4, 119.7, 39.0, 22.3, 13.5; HRMS (ESI-TOF) calcd. For $C_{28}H_{22}N_3O$ (M+H)⁺ m/z = 416.1763, found 416.1761.

6-Isopropyl-10-(naphthalen-1-yl)-13*H*-quinazolino[3,4-*a*]quinazolin-13-one (4k).

102 mg, 62%, pale brown solid: mp 126-127 °C: ¹H NMR (400 MHz, CDCl₃) δ 8.81 (d, *J* = 2.0 Hz, 1H), 8.33 (dd, *J* = 8.4, 1.6 Hz, 1H), 7.93 (d, *J* = 8.0, 1.6 Hz, 1H), 7.83 (t, *J* = 8.8 Hz, 2H), 7.85-7.80 (m, 2H), 7.73-7.69 (m, 1H), 7.61-7.58 (m, 2H), 7.51 (t, *J* = 8.0 Hz, 1H), 7.47-7.44 (m, 2H), 7.42-7.38 (m, 1H), 3.80 (hept, *J* = 6.8 Hz, 1H), 1.45 (d, *J* = 6.8 Hz, 6H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 167.5, 157.4, 153.3, 142.9, 140.8, 138.2, 136.8 (2C), 133.7, 131.8, 131.2, 128.3 (2C), 128.1, 127.9, 127.5, 127.4, 126.5, 126.4, 125.8, 125.3, 125.2, 123.1, 120.3, 119.6, 33.6, 22.4; HRMS (ESI-TOF) calcd. For C₂₈H₂₂N₃O (M+H)⁺ m/z = 416.1763, found 416.1760. **6-Benzyl-10-(naphthalen-1-yl)-13***H***-quinazolino[3,4-***a***]quinazolin-13-one (4I) and 6-benzylidene-10-(naphthalen-1-yl)-6,7-dihydro-13***H***-quinazolino[3,4-***a***]quinazolin-13-one**

(4l').

116 mg, 63% (**41** : **41**' = 1: 0.47), pale yellow solid: mp 132-133 °C; ¹H NMR (400 MHz, CDCl₃) δ 8.79 (d, J = 2.0 Hz, 1H), 8.28 (dd, J = 8.0, 1.6 Hz, 1H), 7.95 (dd, J = 8.0, 2.0 Hz, 1.52 H), 7.89 (d, J = 8.4 Hz, 1.52 H), 7.87-7.85 (m, 2H), 7.82-7.79 (m, 2H), 7.77-7.72 (m, 1H), 7.74-7.70 (m, 0.90 H), 7.57 (ddd, J = 15.0, 7.2, 0.8 Hz, 1H), 7.53-7.45 (m, 2H), 7.44-7.41 (m, 2H), 7.40-7.37 (m, 2H), 7.35-7.31 (m, 1H), 7.29-7.26 (m, 3.5 H), 7.25-7.23 (m, 2.36H), 7.12 (t, J = 7.2 Hz, 0.47 H), 6.25 (brs, 0.79 H), 4.59 (s, 2H), 4.20 (s, 0.94 H); ¹³C {¹H} NMR (100 MHz, CDCl₃) δ 167.2, 165.1, 161.8, 153.3, 150.0, 142.6, 141.2, 138.6, 138.4, 138.1, 136.9, 136.7, 135.6, 135.5, 133.7, 133.6, 131.9, 131.2, 131.1, 129.3, 128.9, 128.5, 128.4, 128.3, 128.2, 128.1, 127.5, 127.4, 127.2, 126.5, 126.46, 126.40, 126.3, 125.9, 125.4, 125.3, 123.0, 122.8, 120.6, 119.8, 112.4, 45.5, 42.8; HRMS (ESI-TOF) calcd. For C₃₂H₂₂N₃O (M+H)⁺ m/z = 464.1763, found 464.1766.

2,6-Dimethyl-13*H*-quinazolino[3,4-*a*]quinazolin-13-one (5a).

65 mg, 63%, brown solid: mp 224-225 °C: ¹H NMR (400 MHz, CDCl₃) δ 8.67 (d, *J* = 8.0 Hz, 1H), 8.16 (s, 1H), 7.79-7.76 (m, 1H), 7.67-7.60 (m, 2H), 7.55-7.51 (m, 2H), 2.95 (s, 3H), 2.49 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 167.4, 153.0, 148.2, 143.3, 138.6, 134.7, 134.5, 132.9, 128.0 (2C), 126.7, 126.1, 122.8, 120.2, 119.8, 26.1, 20.9; HRMS (ESI-TOF) calcd. For C₁₇H₁₄N₃O (M+H)⁺ m/z = 276.1137, found 276.1144.

3-Bromo-6-methyl-13*H*-quinazolino[3,4-*a*]quinazolin-13-one (5b).

37 mg, 36%, brown solid: mp 248-249 °C: ¹H NMR (400 MHz, CDCl₃) δ 8.66 (dd, J = 8.0, 0.8 Hz, 1H), 8.23 (d, J = 8.0 Hz, 1H), 7.89 (d, J = 1.6 Hz, 1H), 7.81 (ddd, J = 15.2, 7.4, 1.2 Hz, 1H), 7.80-7.75 (m, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.56 (t, J = 8.0 Hz, 1H), 2.97 (s, 3H); ¹³C {¹H} NMR (100 MHz, CDCl₃) δ 166.7, 153.5, 147.6, 143.2, 137.5, 135.2, 131.6, 129.9, 128.3, 126.8, 126.6, 126.4, 123.3, 121.7, 119.6, 26.0; HRMS (ESI-TOF) calcd. For C₁₆H₁₁⁷⁹BrN₃O (M+H)⁺ m/z = 340.0085, found 340.0086; HRMS (ESI-TOF) calcd. For C₁₆H₁₁⁸¹BrN₃O (M+H)⁺ m/z = 342.0065, found 342.0081.

2-Iodo-6-methyl-13*H*-quinazolino[3,4-*a*]quinazolin-13-one (5c).

34 mg, 33%, brown solid: mp 152-153 °C: ¹H NMR (400 MHz, CDCl₃) δ 8.71 (d, J = 2.0 Hz, 1H), 8.66 (d, J = 8.0 Hz, 1H), 8.01 (dd, J = 8.8, 1.6 Hz, 1H), 7.82 (t, J = 8.0 Hz, 1H), 7.68 (d, J = 8.0 Hz, 1H), 7.56 (t, J = 8.0 Hz, 1H), 7.48 (d, J = 8.8 Hz, 1H), 2.95 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 165.8, 153.3, 147.6, 143.3, 140.6, 137.2, 136.2, 135.2, 128.3, 126.9, 126.3, 124.2, 121.9, 119.6, 93.0, 26.0; HRMS (ESI-TOF) calcd. For C₁₆H₁₁IN₃O (M+H)⁺ m/z = 387.9947, found 387.9961.

Benzyl 6-methyl-13-oxo-13*H*-quinazolino[3,4-*a*]quinazoline-2-carboxylate (5d).

34 mg, 33%, brown sticky solid: ¹H NMR (400 MHz, CDCl₃) δ 8.66 (d, *J* = 8.0 Hz, 1H), 8.49 (s, 1H), 8.41 (d, *J* = 8.0 Hz, 1H), 8.24 (d, *J* = 8.0 Hz, 1H), 7.83-7.79 (m, 1H), 7.69 (d, *J* = 8.0 Hz, 1H), 7.56 (t, *J* = 7.6 Hz, 1H), 7.45-7.41 (m, 2H), 7.39-7.33 (m, 3H), 5.41 (s, 2H), 2.98 (s, 3H);

¹³C{¹H} NMR (100 MHz, CDCl₃) δ 166.6, 164.6, 153.8, 147.9, 143.4, 136.6, 135.2, 135.1, 133.2, 128.8, 128.7 (2C), 128.5, 128.4, 128.3, 126.8, 126.4, 125.7, 122.1, 119.5, 67.8, 26.0; HRMS (ESI-TOF) calcd. For C₂₄H₁₈N₃O₃ (M+H)⁺ m/z = 396.1348, found 396.1362.

Methyl 2-(4-imino-2-methylquinazolin-3(4*H*)-yl)-3-methylbenzoate (6).

85 mg, 73%, off-white solid: mp 95-96 °C: ¹H NMR (400 MHz, CDCl₃) δ 8.43 (d, *J* = 8.0 Hz, 1H), 8.07 (dd, *J* = 8.0, 1.2 Hz, 1H), 7.69 (ddd, *J* = 15.4, 7.6, 1.6 Hz, 1H), 7.66-7.64 (m, 1H), 7.61-7.53 (m, 2H), 7.45 (ddd, *J* = 15.0, 7.6, 0.8 Hz, 1H), 5.07 (brs, 1H), 3.68 (s, 3H), 2.18 (s, 3H), 2.05 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 164.6, 155.8, 152.4, 144.9, 137.5, 136.4, 135.4, 134.2, 130.9, 130.3, 128.0, 127.1, 127.0, 125.8, 117.7, 52.6, 23.3, 17.3; HRMS (ESI-TOF) calcd. For C₁₈H₁₈N₃O₂ (M+H)⁺ m/z = 308.1399, found 308.1399.

2-(2,8-Dimethyl-4-oxoquinazolin-3(4H)-yl)benzonitrile (7).

9 mg, 8%%, pale yellow solid: mp 254-255 °C: ¹H NMR (400 MHz, CDCl₃) δ 8.10 (dd, J = 7.6, 0.8 Hz, 1H), 7.87 (dd, J = 7.6, 1.2 Hz, 1H), 7.79 (td, J = 8.0, 1.6 Hz, 1H), 7.64-7.60 (m, 2H), 7.40 (d, J = 7.6 Hz, 1H), 7.35 (t, J = 7.6 Hz, 1H), 2.62 (s, 3H), 2.25 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 162.1, 150.8, 145.8, 140.7, 135.7, 134.2, 122.9 (2C), 129.8, 129.7, 126.5, 124.7, 120.2, 115.1, 113.2, 23.9, 17.3; HRMS (ESI-TOF) calcd. For C₁₇H₁₄N₃O (M+H)⁺ m/z = 276.1137, found 276.1139.

2-(2-methyl-4-oxoquinazolin-3(4H)-yl)benzonitrile (8).¹⁴

42 mg, 4%, brown oil: ¹H NMR (400 MHz, CDCl₃) δ 8.24 (dd, *J* = 8.0, 0.8 Hz, 1H), 7.86 (dd, *J* = 7.6, 0.4 Hz, 1H), 7.81-7.75 (m, 2H), 7.69 (d, *J* = 8.0 Hz, 1H), 7.62 (t, *J* = 8.0 Hz, 1H), 7.47 (t, *J* = 7.6 Hz, 1H), 7.42 (d, *J* = 7.6 Hz, 1H), 2.24 (s, 3H); ¹³C{¹H} NMR (100 MHz, CDCl₃) δ 161.5, 152.5, 147.0, 140.3, 135.1, 134.3, 133.9, 130.0, 129.6, 127.1, 126.9 (2C), 120.2, 114.9, 113.2, 23.5; HRMS (ESI-TOF) calcd. For C₁₆H₁₂N₃O (M+H)⁺ m/z = 262.0980, found 262.0981. ASSOCIATED CONTENT

Supporting Information

Spectra for all new compounds. The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.joc.xxxxx

AUTHOR INFORMATION

Corresponding Author

*E-mail: stliu@ntu.edu.tw

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We thank the Ministry of Science and Technology, Taiwan (Grant No. MOST107-2113-M-002-005) for the financial support. We also thank "National Taiwan University Mass Spectrometrybased Proteomics Core Facility" for the measurement of ESI mass data.

References:

1. (a) Stepien, M.; Gonka, E.; Zyla, M.; Sprutta, N. Heterocyclic Nanographenes and Other Polycyclic Heteroaromatic Compounds: Synthetic Routes, Properties and Applications. *Chem. Rev.* **2017**, *117*, 3479-3716. (b) Kaur, N. Microwave-Assisted Synthesis of Fused Polycyclic Six-Membered *N*-Heterocycles. *Synth. Commun.* **2015**, *45*, 273-299, and references therein.

2. (a) Almansour, A. I.; Arumugam, N.; Kumar, R. S.; Mahalingam, S. M.; Sau, S.; Bianchini, G.; Menendez, J. C.; Altaf, M.; Ghabbour, H. A. Design, Synthesis and Antiproliferative Activity of Decarbonyl Luotonin Analogues. *Eur. J. Med. Chem.* **2017**, *138*, 932-941. (b) Kwoon, S. H.; Seo, H. A.; Cheon, C. H. Total Synthesis of Luotonin A and Rutaecarpine From an Aldimine via The Designed Cyclization. *Org. Lett.* **2016**, *18*, 5280-5283. (c) Tseng, M.-C.; Chu, Y.-W.; Tsai, H.-P.; Lin, C.-M.; Huang, J.; Chu, Y.-H. One-Pot Synthesis of Luotonin A and its Analogues. *Org. Lett.* **2011**, *13*, 920-923.

3. (a) Reddy, B. V. S.; Babu, R. A.; Reddy, B. J. M.; Sridhar, B.; Murthy, T. R.; Pranathi, P.; Kalivendi, S. V.; Rao, T. P. Short and Highly Convergent Approach for the Synthesis of Rutaecarpine Derivatives. *RSC Adv.*, **2015**, *5*, 27476-27480. (b) Wang, S.; Yamamoto, S.; Kogure, Y.; Zhang, W.; Nouchi, K.; Dai, Y. Partial Activation and Inhibition of TRPV1 Channels by Evodiamine and Rutaecarpine, Two Major Components of the Fruits of Evodia rutaecarpa. *J. Nat. Prod.* **2016**, *79*, 1225-1230. (c) Kong, X. F.; Zhan, F.; He, G. X.; Pan, C. X.; Gu, C. X.; Lu, K.; Mo, D. L.; Su, G. F. Gold-Catalyzed Selective 6-exo-dig and 7-endo-dig Cyclization of Alkyn-Tethered Indoles To Prepare Rutaecarpine Derivatives. *J. Org. Chem.* **2018**, *83*, 2006-2017.

4. (a) Liao, H.; Peng, X.; Hu, D.; Xu, X.; Huang, P.; Liu, Q.; Liu, L. CoCl₂-promoted TEMPO Oxidative Homocoupling of Indoles: Access to Tryptanthrin Derivatives. *Org. Biomol. Chem.* **2018**, *16*, 5669-5706. (b) Mei, G. J.; Bian, C. Y.; Li, G. H.; Xu, S. L.; Zheng, W. Q.; Shi, F. Catalytic Asymmetric Construction of the Tryptanthrin Skeleton via an Enantioselective Decarboxylative (4+2) Cyclization. *Org. Lett.* **2017**, *19*, 3219-3222. (c) Jia, F. C.; Zhou, Z. W.; Xu, C.; Wu, Y. D.; Wu, A. X. Divergent Synthesis of Quinazolin-4(3H)-ones and Tryptanthrins Enabled by a *tert*-Butyl Hydroperoxide/K₃PO₄-Promoted Oxidative Cyclization of Isatins at Room Temperature. *Org. Lett.* **2016**, *18*, 2942-2945.

5. (a) Reddy, U. V. S.; Chennapuram, M.; Seki, K.; Seki, C.; Anusha, B.; Kwon, E.; Okuyama, Y.; Uwai, K.; Tokiwa, M.; Takeshita, M.; Nakano, H. A. Diamino Alcohol Catalyzed Enantioselective Crossed Aldol Reaction of Acetaldehyde with Isatins-A Concise Total Synthesis of Antitumor Agents. *Eur. J. Org. Chem.* **2017**, 3874-3885. (b) Gao, H.; Luo, Z.; Ge, P.; He, J.; Zhou, F.; Zheng, P.; Jiang, J. Direct Catalytic Asymmetric Synthesis of β-Hydroxy Acids from Malonic Acid. *Org. Lett.* **2015**, *17*, 5962-5965.

6. (a) Kaur, R.; Manjal, S. K.; Rawal, R. K.; Kumar, K. Recent Synthetic and Medicinal Perspectives of Tryptanthrin. *Bioorg. Med. Chem.* 2017, *25*, 4533-4552. (b) Kamal, A.; Reddy, B. V. S.; Sridevi, B.; Ravikumar, A.; Venkateswarlu, A.; Sravanthi, G.; Sridevi, J. P.; Yoeeswari, P.; Sriram, D. Synthesis and Biological Evaluation of Phaitanthrin Congeners As Anti-Mycobacterial Agents. *Bioorg. Med. Chem. Lett.* 2015, *25*, 3867-3872. (c) Kang, G.; Luo, Z.; Liu, C.; Gao, H.; Wu, Q.; Wu, H.; Jiang, J. Amino Acid Salts Catalyzed Asymmetric Aldol Reaction of Tryptanthrin: A Straightforward Synthesis of Phaitanthrin A and Its Derivatives. *Org. Lett.* 2013, *15*, 4738-4741.

7. (a) Ghosh, S. K.; Nagarajan, R. T. Total Synthesis of Cruciferane via Epoxidation/Tandem Cyclization Sequence. *RSC Adv.*, **2014**, *4*, 63147-63149. (b) Vaidya, S. D.; Argade, N. P. Aryne Insertion Reactions Leading to Bioactive Fused Quinazolinones: Diasteroselective Total Synthesis of Cruciferane. *Org. Lett.* **2013**, *15*, 4006-4009.

8. (a) Ozaki, K. I.; Yamada, Y.; Oine, T. Studies on 4(1*H*)-Quinazolinones. IV. Convenient Syntheses of 12-Methyl-6*H*-isoquino (2,1-*a*)quinazolin-6-one and 6-Methyl-13*H*-quinazolino (3,4-*a*) quinazolin-13-one. *Chem. Pharm. Bull.* **1984**, *32*, 2160-2164. (b) Venkateswarlu, S.; Satyanarayana, M.; Murthy, G. N.; Siddaiah, V. Cyclisation of 2-(2-aminophenhl)quinazolin-4(3*H*)-one reexamined: Formation of Isomeric Angular Fused Quinazolinoquinazolinones and Their Spectroscopic Identification. *Tetrahedron. Lett.* **2012**, 53, 2643-2646. (c) Marinho, E.; Araujo, R.; Proença, F. The Reaction of Anthranilonitrile and Triethylorthoformate Revisited: Formation of Dimeric and Trimeric Species. *Tetrahedron* **2010**, *66*, 8681-8689. (d) Calestani, G.; Capella, L.; Leardine, R.; Minozzi, M.; Nanni, D.; Papa, R.; Zanardi, G. thesis and X-ray Characterization of a New Polycondensed Heterocycle Obtained by a Novel Mn(III)-Mediated Cascade Reaction of 2-Cyanophenyl Isothiocyante. *Tetrahedron* **2001**, *57*, 7221-7233.

9. (a) Ghosh, I.; Marzo, L.; Das, A.; Shaikh, R.; Koenig, B. Visible Light Mediated Photoredox Catalytic Arylation Reactions. *Acc. Chem. Res.* 2016, 49, 1566-1577. (b) Mo, F.; Dong, G.; Zhanga, Y.; Wang, J. Recent Applications of Arene Diazonium Salts in Organic Synthesis. *Org. Biomol. Chem.* 2013, *11*, 1582-1593. (c) Sun, C. L.; Shi, Z. J. Transition-Metal-Free Coupling Reactions. *Chem. Rev.* 2014, *114*, 9219-9280. (d) Roglans, A.; Quintana, A. P.; Manas, M. M. Diazonium Salts as Substrates in Palladium-Catalyzed Cross-Coupling Reactions. *Chem. Rev.* 2006, *106*, 4622-4643.

10. (a) Youn, S. W.; Yoo, H. J.; Lee, E. M.; Lee, S. Y. Metal-Free One-Pot Synthesis of (Tetrahydro)Quinolines through Three-Component Assembly of Arenediazonium Salts, Nitriles, and Styrenes. *Adv. Synth. Catal.* 2017, *359*, 1–7. (b) van Dijk, T.; Slootweg, J. C.; Lammertsma, K. Nitrilium ions-synthesis and applications. *Org. Biomol. Chem.* 2017, *15*, 10134-10144. (c) Saez, R.; Otero, M. D.; Batanero, B.; Barba, F. Microwave Reactions of Diazonium Salts with Nitriles. *J. Chem. Res.* 2008, 492-494, and references therein.

11. (a) Ramanathan, M.; Wang, Y. H.; Liu, Y. H.; Peng, S. -M.; Cheng, Y.-C.; Liu, S.-T. Preparation of Ketimines from Aryldiazonium Salts, Arenes, and Nitriles via Intermolecular

Arylation of N-Arylnitrilium Ions. J. Org. Chem. 2018, 83, 6133-6141. (b) Ramanathan, M.; Liu, Y.-H.; Peng, S.-M.; Liu, S.-T. Substituted Quinazolin-4(3H)-imines From Aryldiazonium Salts, Nitriles and 2-Cyanoanilines via A Metal-Free Tandem Approach. Org. Lett. 2017, 19, 5840-5843. (c) Ramanathan, M.; Liu, S.-T. Cascade Annulations of Aryldiazonium salts, Nitriles and Halo-alkynes Leading to 3-Haloquinolines. Tetrahedron, 2017, 73, 4317-4322. (d) Ramanathan, M.; Liu, S.-T. Preparation of Quinazolines via a 2+2+2 Annulation from Aryldiazonium Salts and Nitriles. J. Org. Chem. 2017, 82, 8290-8295. (e) Ramanathan, M.; Wang, Y. H.; Liu, S.-T. One-Pot Reactions for Synthesis of 2,5-Substituted Tetrazoles from Aryldiazonium Salts and Amidines. Org. Lett. 2015, 17, 5886-5889. (f) Ramanathan, M.; Liu, S.-T. Preparation of Substituted Phenanthridines from the Coupling of Aryldiazonium Salts with Nitriles: A Metal Free Approach. J. Org. Chem. 2015, 80, 5329-5336. (g) Youn, S. W.; Lee, E. M. Metal-Free One-Pot Synthesis of N, N'-Diarylamidines and N-Arylbenimidazoles From Aryldiazonium Salts, Nitriles, and Free Anilines. Org. Lett. 2016, 18, 5728-5731.

12. (a) Dou, G.; Shi, D. Efficient and Convenient Synthesis of Indazol-3(2H)-ones and 2-Aminobenzonitriles. J. Comb. Chem. 2009, 11, 1073–1077. (b) Pang, X.; Chen, C.; Su, X.; Li, M.; Wen, L. Diverse Tandem Cyclization Reactions of o-Cyanoanilines and Diaryliodonium Salts with Copper Catalyst for the Construction of Quinazolinimine and Acridine Scaffolds. Org. Lett. 2014, 16, 6228-6231. (c) Lambert, C.; Kriegisch, V. Heteerogeneous Electron Transfer Processes in Self-Assembled Monolayers of Amine Terminated Conjucated Molecular Wires. Langmuir 2006, 22, 8807-8812. (d) Jiang, J.; Lai, Y. H. Evidence for Homo-Conjugation between Two Revolving 14∂-Electron Systems in 10b-Methyl-10c-[2-(10b,10c-dimethyl-10b,10c-dihydropyrenyl)]-10b,10c-dihydropyrene J. Am. Chem. Soc. 2003, 125, 14296-14297. (e) Wu, X.; Gao, Q.; Geng, X.; Zhang, J.; Wu, Y. D.; Wu, A. X. Iodine-Promoted Oxidative Cross-Coupling of Unprotected Anilines with Methyl Ketones: A Site-Selective Direct C–H Bond Functionalization to C4-Dicarbonylation of Anilines. Org. Lett., 2016, 18, 2507–2510.

13. Heinrich, M. R.; Blank, O.; Ullrich, D.; Kirschstein, M. Allylation and Vinylation of Aryl Radicals Generated from Diazonium Salts. *J. Org. Chem.*, **2007**, *72*, 9609-9616.

14. Okuda, K.; Tagata, T.; Kashino, S.; Hirota, T.; Sasaki, K. Polycyclic *N*-heterocyclic Compounds. Part 60: Reactions of 3-(2-cyanophenyl)quinazolin-4(3*H*)-ones with Primary Amines. *Chem. Pharm. Bull.* **2009**, *57*, 1296-1299.